Antonello Mai

Pubblicazioni

Titolo Pubblicato in Anno
HDAC1/2 control mesothelium/ovarian cancer adhesive interactions impacting on Talin-1-α5β1-integrin-mediated actin cytoskeleton and extracellular matrix protein remodeling JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 2024
SIRT3 Activation a Promise in Drug Development? New Insights into SIRT3 Biology and Its Implications on the Drug Discovery Process JOURNAL OF MEDICINAL CHEMISTRY 2024
Mechanisms of mesothelial cell response to viral infections: HDAC1-3 inhibition blocks poly(I:C)-induced type I interferon response and modulates the mesenchymal/inflammatory phenotype FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY 2024
Specific Inhibitors of Mitochondrial Deacylase Sirtuin 4 Endowed with Cellular Activity JOURNAL OF MEDICINAL CHEMISTRY 2024
Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer CANCER CELL INTERNATIONAL 2024
Theileria parasites sequester host eIF5A to escape elimination by host-mediated autophagy NATURE COMMUNICATIONS 2024
Uracil- and Pyridine-Containing HDAC Inhibitors Displayed Cytotoxicity in Colorectal and Glioblastoma Cancer Stem Cells CHEMMEDCHEM 2024
Heterocycles-Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years CHEMMEDCHEM 2024
A host-directed oxadiazole compound potentiates antituberculosis treatment via zinc poisoning in human macrophages and in a mouse model of infection PLOS BIOLOGY 2024
m6A modification inhibits miRNAs’ intracellular function, favoring their extracellular export for intercellular communication CELL REPORTS 2024
STRUCTURE-BASED MECHANISM OF RIBOREGULATION OF THE METABOLIC ENZYME SHMT1 MOLECULAR CELL 2024
Pharmacological Activation of SIRT3 Modulates the Response of Cancer Cells to Acidic pH PHARMACEUTICALS 2024
HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks CELL DEATH DISCOVERY 2024
Systematic Design of Adenosine Analogs as Inhibitors of a Clostridioides difficile-Specific DNA Adenine Methyltransferase Required for Normal Sporulation and Persistence JOURNAL OF MEDICINAL CHEMISTRY 2023
METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry Journey JOURNAL OF MEDICINAL CHEMISTRY 2023
Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 2023
LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials FRONTIERS IN PHARMACOLOGY 2023
GreenMedChem- the challenge in the next decade toward eco-friendly compounds and processes in drug design GREEN CHEMISTRY 2023
Role of SIRT3 in Microgravity Response: A New Player in Muscle Tissue Recovery CELLS 2023
Antihistamines, phenothiazine-based antipsychotics, and tricyclic antidepressants potently activate pharmacologically relevant human carbonic anhydrase isoforms II and VII JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 2023

ERC

  • PE5_18

KET

  • Life-science technologies & biotechnologies

Interessi di ricerca

Synthesis of new potential bio-active compounds, particularly in the field of

  1. epigenetics: inhibitors of HDACs (unselective and class-selective), HATs, sirtuins, PRMTs, HKMTs, KDMs and DNMTs.
  2. anticancer agents.
  3. antiviral agents and anti-HIV-1 compounds belonging to the non-nucleoside reverse transcriptase inhibitor classes
  4. antibacterial, antimycobacterial and antifungal agents.
  5. CNS agents
  6. Development of new methodology for the synthesis of heterocycles. Analysis and purification of organic mixtures. Study and characterization of organic molecules.

Keywords

drug discovery
Epigenetic drugs
antiviral agents
Anticancer drugs
parasite growth inhibition

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma